FDA Egrifta WR Prescribing Information 2025

FDA NDA 22-505

FDA

Summary

Egrifta WR approved 2025-03-25

Study Details

Study Design

FDA-approved drug labeling

Indication

HIV lipodystrophy

Intervention

1.28 mg subcutaneous